期刊文献+

他汀类降血脂药物对曲霉的体外抗真菌作用 被引量:1

In vitro effects of lovastatin and simvastatin against clinical isolates of Aspergillus species
原文传递
导出
摘要 目的观察降血脂药物洛伐他汀、辛伐他汀对曲霉体外抗真菌活性,以及它们与唑类抗真菌药、两性霉素B的联合抗曲霉作用。方法分别用纸片扩散法和微量液基稀释法,测定洛伐他汀、辛伐他汀对烟曲霉、黄曲霉、土曲霉和黑曲霉的抗菌活性。用纸片扩散法、琼脂扩散联合Etest法测两种药物与伊曲康唑、伏立康唑、两性霉素B的联合抗曲霉作用。结果纸片扩散法显示洛伐他汀、辛伐他汀有体外抗曲霉活性。洛伐他汀、辛伐他汀对烟曲霉的最低抑菌浓度(MIC)范围分别为8.128μg/mL、4~64μg/mL;最低杀菌浓度(MFC)与MIC的差异在2个稀释度内。对于非烟曲霉,48h时,20μg洛伐他汀或辛伐他汀不能产生清晰抑菌圈。洛伐他汀、辛伐他汀对黄曲霉的MIC分别为128μg/mL和64μg/mL;两者对土曲霉和黑曲霉的MIC均〉256μg/mL。洛伐他汀、辛伐他汀与伊曲康唑、伏立康唑、两性霉素B均无协同作用。结论在体外,洛伐他汀、辛伐他汀有抗曲霉活性;但与唑类抗真菌药、两性霉素B无协同作用。 Objective To evaluate the in vitro activity of lovastatin and simvastatin, alone or in combination with azoles or amphotericin B against clinical isolates of Aspergillus species. Methods The antifungal activities of both statins against A. fumigatus, A. flavus, A. terreus, and A. niger strains were tested with disk diffusion assay and standard broth microdilution method. The interactive effects between the statins and itraconazole, voriconazole and amphotericin B against Aspergillus spp. were examined with disk diffusion assay, and agar dilution plus E-test methods, respectively. Results As demonstrated by disk diffusion method, lovastatin and simvastatin were active against Aspergillus spp.. The MIC ranges of lovastatin and simvastatin at 48 h were 8-128 μg/mL and 4-64μg/mL, respectively, and the difference between their MFCs and MICs was within 2-fold dilution. However, 20μg of either of the statins could not produce clear inhibition zone against non-fumigatus aspergillus. The MICs of lovastatin and simvastatin at 48 h were 128 μg/mL and 64 μg/mL against A. flavus, respectively, and 〉 256 μg/mL against both A. terreus and A. niger. No synergism was observed in the effects against Aspergillus spp. between the statins and itraconazole, voriconazole or amphotericin B. Conclusions Both lovastatin and simvastatin are active against Aspergillus spp., and there is no synergism between them and azoles or amphotericin B in this effect.
出处 《中华皮肤科杂志》 CAS CSCD 北大核心 2008年第2期118-120,共3页 Chinese Journal of Dermatology
基金 国家自然科学基金(30500027)和教育部留学归国人员启动基金
关键词 曲霉菌属 微生物敏感性试验 洛伐他汀 斯伐他汀 药物相互作用 Aspergillus Microbial sensitivity tests Lovastatin Simvastatin Drug interactions
  • 相关文献

参考文献5

  • 1Chen J, Li H, Li R, et al. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma. J Antimicrob Chemother, 2005, 55(1 ): 31-37.
  • 2郝飞,阎衡,叶庆佾.31例深部真菌病临床和尸检分析[J].中华皮肤科杂志,2003,36(8):441-442. 被引量:29
  • 3Chamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrob Agents Chemother, 2006, 50( 1 ): 96-103.
  • 4National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of illamentous fungi: approved standard. NCCLS document M38-A. Wayne, PA: National Committee for Clinical Laboratory Standards, 2002.
  • 5Espinel-Ingroff A, Fothergill A, Peter J, et al. Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol, 2002, 40(9): 3204-3208.

二级参考文献8

  • 1Tomee JF;van der Werf TS.Pulmonary aspergillosis[J],2001(5).
  • 2de Marie S.New developments in the diagnosis and management of invasive fungal infections,2000.
  • 3Forster DH;Becker A;Kniehl E.Early diagnosis of invasive aspergillosis,2000.
  • 4VandenBergh MF;Verweij PE;Voss A.Epidemiology of nosocomial fungal infections:invasive aspergillosis and the environment[J],1999(3).
  • 5Denning DW.Treatmentofinvasiveaspergillosis,1994(Suppl 1).
  • 6Meis JF;Verweij PE.Current management of fungal infection[J],2001(Suppl).
  • 7Ellis M.Invasive fungal infections:evolving challenges for diagnosis and therapeutics[J],2002(38).
  • 8杜晨,李若瑜,马圣清,王端礼.烟曲霉组氨酸激酶基因片段的隆及表达分析[J].中华皮肤科杂志,2001,34(5):349-351. 被引量:2

共引文献28

同被引文献12

  • 1Kontoyiannis DP, Bodey GP. Invasive aspergillosis in 2002: an update. Eur J Clin Microbiol Infect Dis, 2002, 21 (3): 161-172.
  • 2Loussert C, Schmitt C, Prevost MC, et al. In vivo biofilm compo- sition of Aspergillus fumigatus. Cell Microhiol, 2010, 12(3): 405-410.
  • 3Costerton JW, Lewandowski Z, Caldwell DE, et al. Microbial biofilms. Annu Rev Microbiol, 1995, 49( 1 ): 711-745.
  • 4Ramage G, Vandewalle K, Wiekes BL, et al. Characteristics of biofilm formation by Candida albicans. Rev Iberoam Micol, 2001, 18(4): 163-170.
  • 5Ramage G, Saville SP, Thomas DP, et al. Candida biofilms: an update. Eukaryot Cell, 2005, 4(4): 633-638.
  • 6Clinical and Laboratory Standards Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard-second edition. CLSI document M38-A2. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
  • 7Pierce CG, Uppuluri P, Tristan AR, et al. A simple and repro- ducible 96-well plate-based method for the formation of fungal hiofilms and its application to antifungal susceptibility testing. Nat Protoc, 2008, 3(9): 1494-1500.
  • 8Mowat E, Butcher J, Lang S, et al. Development of a simple model for studying the effects of antifungal agents on multicellu- lar communities of Aspergillus fumigatus. J Med Microbiol, 2007, 56(Pt 9): 1205-1212.
  • 9Ramadan G, Davies B, Kurup VP, et al. Generation of Thl T cell responses directed to a HLA Class H restricted epitope from the Aspergillus f16 allergen. Clin Exp Immunol, 2005, 139(2): 257- 267.
  • 10Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res, 2001, 29(9): e45.

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部